Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 25Nivolumab 25Specimen Handling 18Ipilimumab 16Magnetic Resonance Spectroscopy 12CTLA-4 Antigen 7Opdualag 6Biopsy 6trametinib 5relatlimab 5binimetinib 5dabrafenib 4Paclitaxel 4Cyclophosphamide 4fludarabine 3capivasertib 3atezolizumab 3aldesleukin 3Taxes 3Standard of Care 3Pemetrexed 3Introns 3Interferon alpha-2 3Gemcitabine 3Carboplatin 3Blood Specimen Collection 3ulixertinib 2tislelizumab 2sargramostim 2omipalisib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Paroxetine × 30 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡